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Background: Ustekinumab (UST) is a monoclonal antibody (mAb) that
binds the p40 epitope which is shared by IL-12 and IL-23, whereas
guselkumab (GUS) is a mAb that selectively binds the p19 subunit of
IL-23. In recent studies, both UST (Phase 3 programs) and GUS (Phase
2 program) have demonstrated a reduction in musculoskeletal clinical
signs and symptoms and improvement of psoriatic lesions in patients
with active psoriatic arthritis (PsA), implicating the IL-12/23 pathway in
disease pathogenesis. This analysis explored the post-treatment
pharmacodynamic changes of IL-17A, IL-17F, and CRP with GUS
and UST in the context of PsA.
Methods: Serum protein levels of IL-17A, IL-17F, and CRP were
measured in 142 subjects and 38 matched healthy controls from the
GUS Phase 2 study at Week (W)0, W4, and W16. In the UST Phase 3
studies, biomarkers were assayed at W0, W4, and W24 as follows: IL-
17A (n¼474), IL-17F (n¼237), CRP (n¼927). IL-17A and IL-17F were
assayed using Single Molecule CountingTM Human Immunoassay Kits
(formerly Singulex). CRP was measured using CardioPhase hsCRP
assay (UST studies) or Meso Scale Discovery Platform (GUS study).
Results: At baseline, the Th17 effector cytokines IL-17A and IL-17F
were elevated in the serum of PsA subjects in the GUS Phase 2 cohort
compared to healthy controls. IL-17A and IL-17F levels significantly
correlated with affected skin body surface area, but not swollen or
tender joint scores, in both studies. While none of the baseline levels of
evaluated cytokines were associated with American College of
Rheumatology (ACR) or Psoriasis Area Severity Index (PASI) clinical
responses to UST, baseline IL-17F levels were modestly associated
with ACR20 response to GUS at Week 24. Both UST and GUS
treatment resulted in pharmacodynamic decreases in IL-17A, IL-17F,
and CRP levels, with GUS treatment restoring IL-17A and IL-17F levels
to that of healthy controls by W16. Consistent with being a component
of ACR scores, CRP changes were significantly associated with
ACR20 responses to both UST and GUS treatment. W4 and W16
changes in IL-17F with GUS treatment were significantly associated
with ACR20 response at W24. W24 PASI75 response to GUS was
significantly associated with W4 changes in IL-17A, with a similar trend
observed at W16.
Conclusion: These results underscore the relevance of the IL-23/Th17
pathway in PsA, with GUS treatment providing a stronger suppression
of the pathway than UST treatment. The significant associations of
changes in IL-17A and IL-17F levels with GUS treatment with PASI75
and ACR20 response, respectively, support the importance of the IL-
23/Th17 pathway for both skin and joint pathologies. The associations
of reduction in CRP levels with both UST and GUS treatment also
reinforce the role of acute phase inflammation in joint pathology.
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Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory
disease primarily affecting the spine and sacroiliac joints, charac-
terised by fluctuating periods of flare and remission. Management is
based on patient-reported symptoms and outcome measures col-
lected at follow-up appointments which may be subject to recall bias.
Smartphone technologies for monitoring disease symptoms provide
an opportunity to gain a more complete understanding of disease
burden and symptom patterns and may facilitate optimisation and
personalisation of axSpA management.
Methods: Patients with axSpA attending the Royal National Hospital
for Rheumatic Diseases in Bath were invited to participate in the study.
Through the uMotif symptom tracking app, patients were sent daily
reminders to log pain, fatigue, sleep, recommended exercise, mood
and stress using 5-point Likert scales (higher scores indicating better
outcomes eg. No pain¼5), in addition to optional variables such as
screen time, caffeine intake and menstrual cycle. For each patient, at
each time-point, Spearman rank correlation coefficients were used to
evaluate inter-variable correlations. Lagged variables were used to
assess correlations with variables from the previous day (variable-1).
Results: Between 05/04/18 and 08/03/19, 174 patients consented for
research and logged a mean of 99.73 (SD¼ 99.97) days of data
(range¼1 - 323 days). Significant correlations were identified between
uMotif variables (Table 1), including pain and fatigue; mood and stress;
hot flushes and fatigue/pain; confidence in self-management and
mood/pain; smoking and pain/fatigue; exercise and sleep; exercise
and mood - supporting existing evidence regarding exercise imple-
mentation in axSpA.
Conclusion: These findings demonstrate relationships between a
variety of patient-reported symptoms, including variables that to our
knowledge, have not yet been explored in axSpA. In future research, it
will be important to determine whether there is a chronological pattern
within an individual or combination of variables that could predict a
flare. Greater understanding of axSpA disease patterns and identifica-
tion of the optimal timing of intervention to ameliorate these symptoms
may ultimately reduce flare frequency, duration and intensity, and
greatly improve quality of life for patients with axSpA.
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Pain (N¼171) 1.000 0.526  0.395  0.098  0.423  0.325 
Fatigue (N¼170) 1.000 0.435  0.097  0.441  0.378 
Sleep Quality (N¼ 172) 1.000 0.135  0.411  0.253 
Recommended
Exercise (N¼170)
1.000 0.182  0.128 
Mood (N¼170) 1.000 0.521 
Stress (N¼169) 1.000
Chest pain (N¼ 30) 0.428  0.324  0.229  -0.082  0.188  0.242 
Screen time (N¼25) 0.270  0.248  0.038 -0.069  0.307  0.384 
Caffeine intake (N¼ 67) -0.040  0.075  0.012 0.128  -0.044  -0.029 
Eyesight (N¼29) 0.289  0.235  0.377  0.193  0.460  0.189 
Hydration (N¼56) 0.070  0.109  -0.029  0.183  0.092  0.048 
Hot flushes (N¼18) 0.518  0.555  0.384  0.063  0.386  0.202 
Confidence in self-
management (N¼41)
0.503  0.372  0.336  0.110  0.523  0.370 
Menstrual cycle (N¼ 14) 0.130  0.098  0.045 -0.002 0.100  0.109 
Smoking today (N¼5) 0.394  0.436  0.211 -0.012 0.151 -0.282 
Pain -1 0.719  0.459  0.354  0.095  0.371  0.276 
Fatigue -1 0.454  0.676  0.323  0.074  0.337  0.286 
Sleep Quality -1 0.353  0.342  0.576  0.123  0.336  0.192 
Recommended
Exercise -1
0.094  0.071  0.106  0.587  0.134  0.093 
Mood -1 0.376  0.339  0.338  0.129  0.647  0.360 
Stress -1 0.289  0.309  0.200  0.100  0.361  0.555 
Chest pain -1 0.389  0.307  0.228  -0.072  0.112  0.154 
Screen time -1 0.275  0.218  0.018 -0.101  0.211  0.292 
Caffeine intake -1 -0.037  0.102  0.024 0.116  -0.031  -0.028 
Eyesight -1 0.296  0.202  0.347  0.184  0.439  0.136 
Hydration -1 0.102  0.161  -0.020 0.121  0.100  0.066 
Hot flushes -1 0.481  0.527  0.343  0.088  0.338  0.116 
Confidence in self-
management -1
0.460  0.342  0.298  0.069  0.437  0.297 
Menstrual cycle -1 0.043 0.033 0.050 -0.041 0.048 0.033
Smoking today -1 0.456 0.522  0.023 0.130 -0.036 -0.419
p< 0.05, p< 0.01, p< 0.001; N¼number of patients
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Background: Axial spondyloarthritis (axSpA) is an inflammatory
arthritis predominantly affecting the spine. It is characterised by
chronic back pain, stiffness and fatigue. As axSpA progresses it can
cause disability, reduction in quality-of-life, depression and impacts on
work. Prompt diagnosis is important, but symptoms associated with
axSpA are common in the general population resulting in diagnostic
delay. The reported diagnostic delay for axSpA varies in the literature,
ranging from five to fifteen years. The aim of this review was to
ascertain the extent of axSpA diagnostic delay and report on axSpA
characteristics associated with diagnostic delay.
Methods: A systematic review was conducted to identify articles
reporting diagnostic delay in axSpA. Inclusion criteria were studies
including adult axSpA populations, cohort, cross-sectional or case-
control design and reporting a median time-period of delay from
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mean delay were excluded due to skewness of data). Data was also
extracted which related to delay as a result of specific axSpA
characteristics. Narrative synthesis was used to report our findings.
Results: 9,848 articles were initially identified. After title, abstract and
full-text review, 15 articles reported median diagnostic delay. Of these,
2 were from the UK, 2 from Germany, and 1 each from India, Norway,
France, USA, Iran, Turkey, China and Italy. Combined, the total
number of participants across eligible papers was 10,661. Though
median delay ranged from 1 to 8 years, the majority (60%) of articles
reported a median delay of between 2-5 years. Regarding the role of
specific axSpA characteristics on delay, the most noted causes for
delay were lack of extra-articular axSpA symptoms (5.9 vs. 8.7 years of
delay for patients with and without extra-articular symptoms respec-
tively) and misdiagnosis. Common misdiagnoses were lumbar disc
herniation, rheumatoid arthritis and mechanical back pain (MBP), with
the latter being significantly associated with delayed diagnosis (OR
2.83(95% CI 1.16-6.87)). Finally, delay is far from uniform, with a UK
study reporting that 30.3% of patients are diagnosed within 2 years,
21% in 3-5 years, 19.9% in 6-10 years, 19.2% after 11-20 years and
9.6% after 20 years.
Conclusion: Though diagnostic delay of axSpA is considerable,
affecting long term outcomes in a large number of patients, it is not
as long as previously reported by using mean delay, which is more
affected by bias (long term delays in small numbers of individuals) than
median delay. Further research into the specific barriers and
facilitators of delay is required to help reduce this delay in the future.
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Background: Comparisons of PsA treatment options to guide
physicians are limited. When conventional treatment is insufficient,
the recommendations is a biological agent, most frequently tumour
necrosis factor (TNF)-inhibitors. IXE, an IL-17A antagonist biologic,
showed superiority over TNF-inhibitor ADA for the simultaneous
achievement of ACR50 and PASI100, and PASI100 alone in the
SPIRIT-H2H trial at week 24. We analysed differences in efficacy
outcomes between IXE and ADA by subgroups based on baseline
clinical characteristics.
Methods: We conducted post-hoc analysis of data from SPIRIT-H2H
(NCT03151551), a 52-week, multicentre, open-label, blinded assessor
study patients with active PsA (defined as swollen joint count 3 and
tender joint count 3), with a body surface area (BSA) 3% and
insufficient response to 1 conventional synthetic disease-modifying
anti-rheumatic drugs (csDMARDs) and naı̈ve to biologic (b)-DMARDs.
Patients were randomised 1:1 to IXE or ADA, while presence/absence
of moderate-to-severe psoriasis (defined as PASI 12, static Physician
Global Assessment 3 and BSA 10%) determined on-label dosing.
Subgroups were defined by baseline enthesitis, dactylitis, fingernail
psoriasis (presence/absence), BSA (<10%, 10%) and CRP (6 mg/
L,>6 mg/L). A Fisher’s exact test was used for between group
comparisons of efficacy outcome measures at 24 weeks (PASI90,
ACR50/70, and minimal disease activity [MDA]). Missing data were
overcome by non-responder imputation.
Results: At week 24, IXE and ADA demonstrated comparable efficacy
in ACR50 response rates across all subgroups. ACR70 response in
patients with fingernail psoriasis was significantly greater with IXE-
treated vs ADA (p¼ 0.02) (table). PASI90 response with baseline
enthesitis (p< 0.001), without dactylitis (p<0.001), with fingernail
psoriasis (p<0.001), CRP (6 mg/L, p¼ 0.003; >6 mg/L, p¼ 0.036)
and BSA (<10%, p¼0.010; 10%, p¼0.003) was significantly greater
in IXE vs ADA (table). Significantly more IXE-treated patients vs ADA
achieved MDA with baseline enthesitis (p¼0.002), without dactylitis
(p¼0.015), with fingernail psoriasis (p<0.001), CRP 6 mg/L
(p¼0.046) and BSA 10% (p¼ 0.01) (table). A limitation is that this
analysis was completed post-hoc, not controlled for multiplicity, and
patients were not stratified by baseline disease characteristics.
Conclusion: IXE and ADA are associated with comparable efficacy
and associated with a greater effect in certain subgroups. Results will
aid clinicians when making treatment choices.
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Background: To evaluate the effect of guselkumab (GUS) on Routine
Assessment of Patient Index Data 3 (RAPID3) in patients with psoriatic
arthritis (PsA).
Methods: In a Phase 2 trial, patients with active PsA and 3% body
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